Shell Asset Management Co. Purchases 3,636 Shares of Zoetis Inc. $ZTS

Shell Asset Management Co. boosted its position in Zoetis Inc. (NYSE:ZTS) by 58.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,890 shares of the company’s stock after purchasing an additional 3,636 shares during the quarter. Shell Asset Management Co.’s holdings in Zoetis were worth $1,542,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Nova Wealth Management Inc. bought a new stake in Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC bought a new stake in Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank bought a new stake in Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the period. Finally, ORG Partners LLC lifted its position in shares of Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after acquiring an additional 84 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $143.61 on Thursday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The business has a fifty day simple moving average of $149.41 and a 200 day simple moving average of $154.74. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market cap of $63.65 billion, a P/E ratio of 24.72, a P/E/G ratio of 2.29 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the firm earned $1.56 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ZTS shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus reiterated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.